研究業績

論文・出版

Effectiveness of Fulvestrant in Advanced or Metastatic Breast Cancer Patients in the Real World: A Retrospective Multi-center Cohort Study with 1072 Patients (JBCRG-C06; Safari)


H Kawaguchi, N Masuda, T Nakayama, K Aogi, K Anan, Y Ito, S Ohtani, N Sato, S Saji, E Tokunaga, S Nakamura, Y Hasegawa, M Hattori, T Fujisawa, S Morita, M Yamaguchi, T Yamashita, Y Yamamoto, S Ohno, and M Toi.


Breast Cancer Research and Treatment 2017 Jun;163(3):545-554. doi: 10.1007/s10549-017-4212-x. Epub 2017 Mar 23.

Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients (JBCRG-C01)


Hiroyasu Yamshiro · Hiroji Iwata · Norikazu Masuda · Naohito Yamamoto · Reiki Nishimura · Shoichiro Ohtani · Nobuaki Sato · Masato Takahashi · Takako Kamio · Kosuke Yamazaki · Tsuyoshi Saito · Makoto Kato · Tecchuu Lee · Shinji Ohno · Katsumasa Kuroi · Toshimi Takano · Masahiro Takada · Shinji Yasuno · Satoshi Morita · Masakazu Toi


International Journal of Clinical Oncology Volume 20, Issue 4 (2015), Page 709-722. doi: 10.1007/s10147-015-0785-8.

ネオアジュバント化学療法後の再発リスクが高いホルモン受容体陽性HER2陰性原発性乳癌患者を対象としたサイクリン依存性キナーゼ(CDK)4/6阻害薬palbociclib(PD-0332991)を評価する第III相試験「PENLOPE試験」


岩田 広治


CANCER BOARD乳癌 Vol.7 N0.2 2014年(デザインペーパー)

ホルモン陽性HER2陰性進行再発乳癌に対する、ホルモン療法による維持療法を利用したベバシズマブ+パクリタキセル療法の治療最適化研究 JBCRG-M04(BOOSTER)


佐治重衡、戸井雅和


CANCER BOARD乳癌 Vol.7 N0.2 2014年(デザインペーパー)

A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer


N. Masuda · K. Higaki · T. Takano · N. Matsunami · T. Morimoto · S. Ohtani · M. Mizutani · T. Miyamoto · K. Kuroi · S. Ohno · S. Morita · M. Toi


Cancer Chemotherapy and Pharmacology. (2014 Aug) 74(2):229-38. doi: 10.1007/s00280-014-2492-y

Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study)


M. Takada, H. Ishiguro, S. Nagai, S. Ohtani, H. Kawabata, Y. Yanagita, Y. Hozumi, C. Shimizu, S. Takao, N. Sato, Y. Kosaka, Y. Sagara, H. Iwata, S. Ohno, K. Kuroi, N. Masuda, H. Yamashiro, M. Sugimoto, M. Kondo, Y. Naito,H. Sasano, T. Inamoto, S. Morita, & M. Toi on behalf of the JBCRG-C03 Collaborative Group


Breast Cancer Research and Treatment 2014 May;145(1):143-53. doi: 10.1007/s10549-014-2907-9.

An Overview of the Japan Breast Cancer Research Group (JBCRG) activities


Shinji Ohno, Katsumasa Kuroi and Masakazu Toi


Breast Cancer. 2013 Oct;20(4):291-5. doi: 10.1007/s12282-012-0420-8.

Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study


Yoshiki Mikami, Takayuki Ueno, Kenichi Yoshimura, Hitoshi Tsuda, Masafumi Kurosumi, Shinobu Masuda, Rie Horii, Masakazu Toi and Hironobu Sasano


Cancer Science November 2013 vol. 104 no. 11 1539–1543. doi: 10.1111/cas.12245

JBCRG (Japan Breast Cancer Research Group)の現況と展望


増田慎三、戸井雅和、黒井克昌他


乳癌(第2版) 日本臨床 70(増刊号7) p763-771、2012 日本臨床社 (大阪)

Neo-LaTH試験(HER2陽性乳癌におけるDual-HER2 blockage療法ホルモン療法の検討:ランダム化第Ⅱ相試験)


増田慎三、戸井雅和、笠井宏委


CANCER BOARD 乳癌5(2):P.71-73、2012年

前のページへ 次のページへ
任意団体JBCRG 研究業績